ORGANIZATION AND PRINCIPAL ACTIVITIES	6 Months Ended
ORGANIZATION AND PRINCIPAL ACTIVITIES	Jun. 30, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 2 – ORGANIZATION AND PRINCIPAL ACTIVITIES Bio-Bridge Science, Inc (the “Company”) was incorporated in the State of Delaware on October 26, 2004. The Company's fiscal year end is December 31. On December 1, 2004, the Company acquired all of the outstanding shares of Bio-Bridge Science Corporation (“BBS”), a Cayman Islands corporation, in exchange for 29,971,590 shares of its common stock, and as a result, BBS became a wholly owned subsidiary of Bio-Bridge Science, Inc. The acquisition was accounted for as a reverse merger (recapitalization) with BBS deemed to be the accounting acquirer, and the Company the legal acquirer. BBS was incorporated in the Cayman Islands on February 11, 2002. At the time of the exchange, BBS held a 100% interest in Bio-Bridge Science (Beijing) Corp. (“Bio-Bridge Beijing”), a wholly foreign-funded enterprise of the People's Republic of China (“PRC”), which was established on May 20, 2002. Bio-Bridge Beijing is currently engaged in the development and commercialization of several vaccine candidates in the PRC, including an HIV-PV vaccine I, a cervical cancer vaccine, and a colon cancer vaccine. In June of 2009, the Company entered into an equity joint venture contract to purchase 51 percent of Bio-Bridge JRS Biosciences (Beijing) Co., Ltd. (“Bio-Bridge JRS”). Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company had a net loss of $742,298 and used cash in operations of $328,154 for the six months ended June 30, 2011, and had an accumulated deficit of $17,218,388 as of June 30, 2011. These factors raise substantial doubt about the Company’s ability to continue as a going concern, which is dependent upon the Company’s ability to raise additional funds to implement its business plan. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. We are maintaining minimum operating activities at BBS Beijing due to low liquidity. During the three months ended June 30, 2011, the Company has drawn down on its business line of credit, the balance of which is $74,700 at June 30, 2011. BBS Beijing obtained short term loans to sustain its operations. We will need to obtain additional financing to fund our cash needs and continue our operations. Additional financing, whether through public or private equity or debt financing, arrangements with stockholders or other sources to fund operations, may not be available, or if available, may be on terms unacceptable to us. Our ability to continue operations is dependent on our ability to raise additional capital. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of our common stock. Debt incurred by us would be senior to equity in the ability of debt holders to make claims on our assets. The terms of any debt issued could impose restrictions on our operations.

BIO BRIDGE SCIENCE INC 10-Q/A